MX2007014672A - Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica. - Google Patents

Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica.

Info

Publication number
MX2007014672A
MX2007014672A MX2007014672A MX2007014672A MX2007014672A MX 2007014672 A MX2007014672 A MX 2007014672A MX 2007014672 A MX2007014672 A MX 2007014672A MX 2007014672 A MX2007014672 A MX 2007014672A MX 2007014672 A MX2007014672 A MX 2007014672A
Authority
MX
Mexico
Prior art keywords
production
monoclonal antibody
nucleic acid
recombinant method
treatment
Prior art date
Application number
MX2007014672A
Other languages
English (en)
Inventor
Villoo Morawala Patell
Original Assignee
Avestha Gengraine Tech Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avestha Gengraine Tech Pvt Ltd filed Critical Avestha Gengraine Tech Pvt Ltd
Publication of MX2007014672A publication Critical patent/MX2007014672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere al metodo recombinante utilizado para la produccion de anticuerpo monoclonal en forma soluble que se enlaza a CD52. El procedimiento describe la sintesis de novo de la secuencia de acido nucleico que codifica anti-CD52, la transformacion de las secuencias de acido nucleico construidas en bacterias competentes y la sub-clonacion de las mismas en vectores de expresion mamiferos para expresion de la proteina deseada. Las construcciones de ADN que comprenden los elementos de control asociados con el gen de interes se han expuesto. La secuencia de acido nucleico de interes ha optimizado el codon para permitir la expresion en las celulas huesped mamiferas adecuadas.
MX2007014672A 2005-05-24 2006-05-24 Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica. MX2007014672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN625CH2005 2005-05-24
PCT/IB2006/001356 WO2006126068A2 (en) 2005-05-24 2006-05-24 Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
MX2007014672A true MX2007014672A (es) 2008-04-08

Family

ID=37452410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014672A MX2007014672A (es) 2005-05-24 2006-05-24 Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica.

Country Status (14)

Country Link
US (1) US20090220520A1 (es)
EP (1) EP1883653A2 (es)
JP (1) JP2009504136A (es)
KR (1) KR20080039843A (es)
CN (1) CN101238150A (es)
AP (1) AP2007004250A0 (es)
AU (1) AU2006250887A1 (es)
BR (1) BRPI0610304A2 (es)
CA (1) CA2609480A1 (es)
IL (1) IL187400A0 (es)
MX (1) MX2007014672A (es)
RU (1) RU2007147414A (es)
WO (1) WO2006126068A2 (es)
ZA (1) ZA200711007B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2167540T1 (en) * 2007-06-29 2018-05-31 F. Hoffmann-La Roche Ag A mutant heavy chain that enables improved production of immunoglobulins
CN101619305B (zh) * 2007-10-19 2013-03-20 协和干细胞基因工程有限公司 抗人cd52单克隆抗体杂交瘤细胞系、单克隆抗体、工程抗体、载体、试剂盒及其用途
CN102459628A (zh) * 2009-05-13 2012-05-16 基酶有限公司 抗人cd52 免疫球蛋白
AU2011223547B2 (en) 2010-03-04 2016-05-05 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
WO2013181568A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to alemtuzumab
WO2014140924A2 (en) * 2013-03-12 2014-09-18 International Park Of Creativity Biological devices and methods for increasing the production of lycopene from plants
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN106018814B (zh) * 2016-08-07 2017-11-14 深圳市南海生物科技有限公司 一种用于白血病和自身免疫病检测用试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation

Also Published As

Publication number Publication date
CA2609480A1 (en) 2006-11-30
AP2007004250A0 (en) 2007-12-31
IL187400A0 (en) 2008-02-09
RU2007147414A (ru) 2009-07-10
US20090220520A1 (en) 2009-09-03
KR20080039843A (ko) 2008-05-07
ZA200711007B (en) 2008-11-26
JP2009504136A (ja) 2009-02-05
BRPI0610304A2 (pt) 2010-06-08
WO2006126068A3 (en) 2007-08-23
WO2006126068A2 (en) 2006-11-30
EP1883653A2 (en) 2008-02-06
CN101238150A (zh) 2008-08-06
AU2006250887A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
MX2007014672A (es) Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica.
WO2006126069A3 (en) A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
Haryadi et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells
CN104804093A (zh) 一种针对cd47的单域抗体
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
CN108026148A (zh) 融合蛋白合成的方法和产品
PL393646A1 (pl) Sposób wytwarzania polipeptydu
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
WO2004061104A3 (en) Method for manufacturing recombinant polyclonal proteins
JP2010536396A5 (es)
MX2009006659A (es) Anticuerpos y metodos de elaboracion y uso.
WO2002000711A3 (en) Ev-vegf nucleic acids and polypeptides and methods of use
WO2003038049A3 (en) Method for isolating cell-type specific mrnas
TW200638944A (en) Recombinant enterovirus 71 neutralizing antibodies and use thereof
DE60144021D1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
CN107603996A (zh) 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法
US9803207B2 (en) Expression vector for production of recombinant proteins in prokaryotic host cells
Diepenbruck et al. Productivity and quality of recombinant proteins produced by stable CHO cell clones can be predicted by transient expression in HEK cells
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
Wu et al. Design, production, and characterization of an engineered biotin ligase (BirA) and its application for affinity purification of staphylokinase produced from Bacillus subtilis via secretion
PT1366161E (pt) Anticorpo anatagonista anti-pro842
CN110386986A (zh) 人工改造蛋白质及其构建方法与应用
WO2006126070A3 (en) A process comprising codon optimization for the production of recombinant activated human protein c for the treatment of sepsis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal